About
A global leader in in vitro diagnostics for over 55 years, bioMérieux contributes to the quality of patient care and the safety of consumers. The company develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. bioMérieux has also applied the expertise acquired in the clinical sector to meeting industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products.
bioMérieux has been supporting TSE researchers since December 2020 to encourage and promote fundamental and applied research on emerging issues in the field of health economics. This partnership has been renewed in 2024, to continue the work undertaken in the first period by carrying out a research project in economic sciences relating to a joint "diagnostic and therapeutic" model to combat antibiotic resistance. A two-pronged approach is envisaged: hospital and outpatient medicine.
Research findings will be shared not only with the scientific community but also with a wider audience in order to raise awareness on these topical issues in the field of health economics.
Research topics
- Optimal innovation and regulatory policy against antibiotic resistance using diagnostic and antibiotic treatments
- Empirical method to evaluate the value of diagnostic tests in the area of antimicrobial resistance.
bioMérieux is a partner of the TSE Health Center.
